The Column Group
QuietFiled to raiseSan Francisco, CALast fund filed January 2025Biotechnology, Pharmaceuticals, Healthcare
San Francisco, CALast fund filed January 2025Biotechnology, Pharmaceuticals, Healthcare
0 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Column Group Opportunity IV, LPFiled to raise, with no closing reported yet. | January 2025 | $600.0M | $0 | 0 |
| Column Group VI, LPFiled to raise, with no closing reported yet. | January 2025 | $600.0M | $0 | 0 |
| Column Group-Neuro II, LP | February 2024 | $100.0M | $100.0M | 3 |
| Column Group SPV I, LP | November 2022 | $10.5M | $10.5M | 1 |
| Column Group Opportunity III, LP | June 2022 | $600.0M | $600.0M | 100 |
| Column Group V, LP | June 2022 | $600.0M | $600.0M | 99 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. Form D carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 0 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats, 24mo |
|---|---|---|---|
| David Goeddel | Quiet | None listed | 0 |
| Peter SvennilsonOn the current fund | Quiet | None listed | 0 |
| Tim KutzkeyOn the current fund | Quiet | Healthcare | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. On a firm it is the total across its partners, so an active firm may be four partners taking one seat each rather than one person moving fast. It undercounts partners who invest without taking a board seat, and Form D lags a closing by weeks — so Quiet means the paperwork is quiet, not the person.